Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of March 29, 2025 • 9:00 PM ET

Date/Time Source News Release
03/19/2025 09:14 AM EDT GlobeNewswire Revive Therapeutics Announces Results of Annual Shareholder Meeting
03/03/2025 08:00 AM EST GlobeNewswire Revive Therapeutics Announces LOI to Acquire DiagnaMed's Molecular Hydrogen Program
02/03/2025 05:00 PM EST GlobeNewswire Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
01/08/2025 07:30 AM EST GlobeNewswire Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
11/12/2024 07:45 AM EST GlobeNewswire Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
10/31/2024 07:30 AM EDT GlobeNewswire Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
09/18/2024 07:00 AM EDT GlobeNewswire Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
08/28/2024 07:00 AM EDT GlobeNewswire Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections
07/02/2024 01:58 PM EDT GlobeNewswire Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
06/12/2024 09:05 AM EDT GlobeNewswire Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
Page

Additional News

As of March 29, 2025 • 9:00 PM ET

Date/Time Source News Release
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.